MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

Inclusion Criteria

• •Advanced unresectable or metastatic melanoma, previously treated with ipilimumab; anti-melanoma treatments, including anti-PD/PD-L1 or any other immunotherapy, are allowed provided no treatment from last dose of that treatment to trial enrolment
• •Subjects need to have
• •* one lesion that can be irradiated
• •* at least 1 measurable lesion outside the radiation field, different from the lesion that will be irradiated
• •* one lesion that can be biopsied before treatment with SBRT and MSB0010445
• •* one lesion outside the radiation field that can be biopsied while on treatment with MSB0010445
• •The lesion that is biopsied at Baseline can be the lesion that will be irradiated
• •The lesion that will be biopsied while on treatment should not be a lesion that has been irradiated or biopsied at Baseline
• •Signed written informed consent
• •Male and female subjects at least 18 years of age
• •Life expectancy greater than or equal to (\>=) 4 months
• •Eastern cooperative oncology group (ECOG) performance status of 0 or 1